Differential Glial Activation in Early Epileptogenesis—Insights From Cell-Specific Analysis of DNA Methylation and Gene Expression in the Contralateral Hippocampus

Toni C. Berger1,2*, Magnus D. Vigeland3†, Hanne S. Hjorthaug3, Cecilie G. Nome2, Erik Taubøll1,2, Kaja K. Selmer3,4,5† and Kjell Heuser1,2†

1 Department of Neurology, Oslo University Hospital, Oslo, Norway, 2 University of Oslo, Oslo, Norway, 3 Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway, 4 Division of Clinical Neuroscience, Department of Research and Innovation, Oslo University Hospital, Oslo, Norway, 5 National Centre for Epilepsy, Oslo University Hospital, Sandvika, Norway

Background and Aims: Morphological changes in mesial temporal lobe epilepsy with hippocampal sclerosis (mTLE-HS) are well-characterized. Yet, it remains elusive whether these are a consequence of seizures or originate from a hitherto unknown underlying pathology. We recently published data on changes in gene expression and DNA methylation in the ipsilateral hippocampus (ILH) using the intracortical kainate mouse model of mTLE-HS. In order to explore the effects of epileptic activity alone and also to further disentangle what triggers morphological alterations, we investigated glial and neuronal changes in gene expression and DNA methylation in the contralateral hippocampus (CLH).

Methods: The intracortical kainic acid mouse model of mTLE-HS was used to elicit status epilepticus. Hippocampi contralateral to the injection site from eight kainate-injected and eight sham mice were extracted and shock frozen at 24 h post-injection. Glial and neuronal nuclei were sorted by flow cytometry. Alterations in gene expression and DNA methylation were assessed using reduced representation bisulfite sequencing and RNA sequencing. The R package edgeR was used for statistical analysis.

Results: The CLH featured substantial, mostly cell-specific changes in both gene expression and DNA methylation in glia and neurons. While changes in gene expression overlapped to a great degree between CLH and ILH, alterations in DNA methylation did not. In the CLH, we found a significantly lower number of glial genes up- and downregulated compared to previous results from the ILH. Furthermore, several genes and pathways potentially involved in anti-epileptogenic effects were upregulated in the CLH. By comparing gene expression data from the CLH to previous results from the ILH (featuring hippocampal sclerosis), we derive potential upstream targets for epileptogenesis, including glial Cox2 and Cxcl10.
INTRODUCTION

Epileptogenesis describes the transformation of a normally functioning brain into an epileptic brain (1, 2). For mesial temporal lobe epilepsy with hippocampal sclerosis (mTLE-HS), this process often involves an initial incident (i.e., prolonged febrile seizure, inflammation, or cerebral trauma), followed by a clinically silent latent phase, and, ultimately, seizures of increasing frequency and severity (3). Pathological hallmarks of mTLE-HS are well-characterized in both humans and in animal models and predominantly consist of progressive neuronal cell death and reactive gliosis (4–14). The underlying mechanisms of these features remain elusive, and their further disentanglement is of paramount importance for the development of truly anti-epileptogenic drugs (15, 16).

In this paper, we use a combined analysis of cell-specific gene expression and DNA methylation to investigate epileptogenesis in a mouse model for mTLE-HS. Gene expression by means of RNA sequencing is a well-established approach for investigating biological function (17, 18). A cell-specific approach, i.e., the separation of neurons and glia prior to downstream analysis, has been used in various previous studies (19–21) and facilitates the detection of more subtle effects and the determination of the cellular origin of the observed DNA methylation and gene expression alterations (22).

DNA methylation contributes to cell-specific gene expression (23–26) and is altered in both epileptic human tissue (27) and animal models of epilepsy (22, 28–30). Amendable by, among other things, neuronal activity (31), nutrition (32), and newer epigenetic tools (33), it represents a modifiable potential upstream mechanism in epileptogenesis.

We recently published a study on neuronal and glial DNA methylation and gene expression changes at 24 h post-kainate-induced status epilepticus, a time point relevant to early epileptogenesis (11, 34). These findings from the ipsilateral hippocampus (ILH) revealed a number of significant gene expression alterations in both neurons and glia. We further found a number of epilepsy-relevant genomic loci with a significant association of differential gene expression and differential DNA methylation (22). These observations originated from the intracortical kainate mouse model, where both hippocampi are exposed to epileptic activity but only the ILH gradually develops morphological changes (e.g., neuronal death and reactive gliosis) similar to human mTLE-HS (11) (Figure 1). In contrast, the contralateral hippocampus (CLH) is only exposed to epileptic activity and regarded as “free from morphological alterations” (11, 35). As such, it is often used as an internal control for the ILH (11).

The aims of this study were to on glia- and neuron-mediated downstream effects of epileptic activity based on gene expression changes in the CLH. We further elaborated on potential upstream targets for hippocampal sclerosis and epileptogenesis within genes exclusively differentially expressed in the ILH (and not CLH). Lastly, we explored the potential role of DNA methylation on cell-specific gene expression in early epileptogenesis.

METHODS

The methods applied in this study follow the same protocol as previously described in Berger et al. (22). Raw data are available under GEO accession GSE153976.

Animals

Adult male C57/BL6N mice (Janvier Labs, France), acquired at an age of 8 weeks, were acclimatized for 4 weeks in a controlled environment (21–23°C, 12-h dark/light cycles). One to four animals were housed per cage, with water and food available ad libitum. All animal procedures were approved by the Norwegian Food Safety Authority (project number FOTS: 14198), the Center for Comparative Medicine, Oslo University Hospital and the University of Oslo.

Intracortical Kainic Acid Mouse Model of Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis

We used the intracortical mouse model for mTLE-HS, described in detail by Bedner et al. (11), to elicit status epilepticus. In brief, the mice were anesthetized with a mixture of medetomidine (0.3 mg/kg, i.p.) and ketamine (40 mg/kg, i.p.) and kept on a heating blanket. For mice in the kainic acid group, kainate (70 nl, 20 mM, Tocris) was injected above the right
FIGURE 1 | Schematic overview: Differential gene expression in the contralateral and ipsilateral hippocampi at 24 h after status epilepticus induction. Both the ipsilateral and contralateral hippocampi were exposed to epileptic activity (upon a status epilepticus lasting several hours), but only the ipsilateral hippocampus gradually develops morphological alterations such as reactive gliosis and neuronal death (hippocampal sclerosis). In this study, gene expression was compared between epileptic mice (kainate injected over the right, ipsilateral, hippocampus) and sham mice (saline injected at the same location) for the contralateral hippocampus (CLH, blue arrow). This data was compared to previous data on gene expression from the ipsilateral hippocampus (ILH, red arrow). Differentially expressed genes associated with epileptic activity are represented by the blue boxes. Differentially expressed genes potentially associated with morphological alterations typical of mesial temporal lobe epilepsy with hippocampal sclerosis (mTLE-HS) are represented by the red box.

Fluorescence-Activated Nuclear Sorting
Cell nuclei were sorted into NeuN+ nuclei (referred to as neurons) and NeuN− nuclei (referred to as glia) by a modified version of Jiang et al. (36) (for technical limitations and restrictions in interpretability, see Limitations). Hippocampi were placed on ice immediately after pooling, and 1 ml homogenization buffer was added. GentleMACS dissociator (Miltenyi) was used to homogenize the tissue. The homogenate was subsequently filtered through a 70-µm filter and debris removed by density gradient centrifugation using Debris Removal Solution (Miltenyi). Nuclear pellets were resuspended in 100 µl incubation buffer per 1 × 10⁶ nuclei and Anti-NeuN Alexa Fluor 488 (Merck Millipore) added (0.1 µg/ml per sample). The samples were incubated for 1 h on ice, protected from light. Adult mouse liver was used as a NeuN-negative control sample and processed in parallel with hippocampal tissue. The nuclei were sorted into NeuN+ and NeuN− fractions using a FACSARia (BD Biosciences), followed by centrifugation, and pellets were resuspended in lysis buffer for DNA and RNA isolation. For further details, see Supplementary Document.

Isolation of DNA and Total RNA From Sorted Nuclei
MasterPure Complete DNA and RNA Purification Kit (Epicenter) was used to extract DNA from sorted nuclei.
DNA purity was evaluated on NanoDrop and the DNA concentration assessed on Qubit (DNA HS assay). Total RNA was extracted using the mirVana miRNA Isolation Kit (Ambion) and RNA was up-concentrated with the RNA Clean & Concentrator-5 kit (Zymo Research). RNA integrity and concentration were analyzed on Bioanalyzer with the RNA Pico Kit (Agilent Technologies). For further details, see Supplementary Document.

Reduced Representation Bisulfite Sequencing

A modified version of the gel-free protocol provided by Boyle et al. (37) was used for reduced representation bisulfite sequencing (RRBS) library preparation. Main changes comprised the inclusion of a two-sided size selection before bisulfite conversion and sample pooling after completion of single libraries. Libraries representing the contralateral and ipsilateral hemispheres were prepared and sequenced in parallel, and sequencing pools contained either 14 libraries run twice on NextSeq500 (50% PhiX spike-in, 75-bp single reads) or 15 libraries sequenced over two lanes on HiSeq2500 (10% PhiX spike-in, 50-bp single reads). The library preparation procedure is described in detail in Supplementary Document.

High-Throughput mRNA Sequencing

SMART-Seqv4 Ultra Low Input RNA Kit for Sequencing (Takara Bio) was used to amplify messenger RNA (mRNA) from total RNA, and the resulting complementary DNA (cDNA) was used as the input in library preparation with the ThruPlex DNAseq Kit (Rubicon Genomics). Libraries representing the contralateral and ipsilateral hemispheres were prepared and sequenced in parallel, and sequencing pools contained either 12 libraries sequenced on NextSeq500 (75-bp single reads) or 27 libraries sequenced over three lanes on HiSeq3000 (150-bp paired-end reads). Details regarding mRNA sequencing (mRNAseq) library preparation are given in Supplementary Document.

Computational Methods

Bioinformatic Handling and Quality Control of mRNAseq Data

The mRNAseq reads were trimmed with Trim Galore! v0.4.3 and aligned by Bowtie2) using the mouse genome mm 10 as reference. The Rbfox3, glial genes (Aldh111, Cx3cr1, and Mbp), as well as pericyte (Pdgfrb) and endothelial (Pecam1) genes were visualized to verify the enrichment of neurons and glia in the NeuN+ and NeuN− fractions. In order to validate our cell sorting procedures and discover outliers, a multidimensional scaling (MDS) plot of the RRBS data set was produced in a similar fashion to the mRNAseq, using the 100 most variable loci.

Bioinformatic Handling and Quality Control of RRBS Data

The RRBS raw data underwent trimming with Trim Galore! v0.4.3, with parameters “-rrbs-illumina,” and quality control with FastQC. Alignment was done with Bismark v0.20 (powered by Bowtie2) using the mouse genome mm 10 as reference. The Picard tool CollectRrsbsMetrics v2.18.15 was used for quality control of the BAM files.

An MDS plot of the RRBS data set was produced in a similar way to the mRNAseq, using the 100 most variable loci. The bisulfite conversion rates were estimated in two ways. Firstly, by picard/CollectRrsbsMetrics, which measures the conversion of non-CpG cytosines. This statistic may be unreliable in neurons, where the methylation of non-CpG cytosines occurs with non-negligible frequency. To account for this, we also performed an alternative estimate of the conversion rates directly from the untrimmed fastq files, targeting the unmethylated cytosines added in the end-prepare step of the RRBS preparation (private bash script). Samples whose conversion rate estimates were below 98% in both methods were excluded.

Annotation

Coordinates of the genes, exons, and introns were obtained from the M16 release of GENCODE’s comprehensive annotation, restricted to autosomal genes. Annotation of Cpg sites was performed with the R package annotatr (40), supplying details of the gene regions overlapping each CpG. In particular, promoter regions were defined as the 1-kb segments upstream of the transcription start sites, and upstream regions were defined as ranging from −5 to −1 kb relative to the transcription start sites.

Analysis of Differential Gene Expression

Analysis of differential gene expression between the kainic acid group and the sham group samples was performed with the R package edgeR (41). Preparatory steps included removal of genes without the official HGNC symbol, removal of genes with a low read count (determined by the edgeR function filterByExpr with default parameters), and normalization adjusting for different library sizes (done with calcNormFactors). The differential gene expression analysis followed a standard edgeR workflow based on a quasi-likelihood negative binomial generalized log-linear model fitted to the count data. Data from glial and neuronal cells were analyzed separately. The significance threshold was set to a false discovery rate (FDR) of 25%.

Analysis of Differential DNA Methylation

Loci exhibiting differential DNA methylation between the kainic acid group and the sham group samples were identified with edgeR, following a workflow for RRBS data recently published by the edgeR authors (42). In brief, this treats the methylated and unmethylated counts at each locus as independent variables following a negative binomial distribution. As for differential gene expression, the differential DNA methylation analysis was carried out separately for neuronal and glial cells, with a
FDR of 25% as the significance threshold. Preparatory steps included removing all CpG sites where more than 10% of the samples had either very low coverage (< 8 reads) or very high coverage (> 99.5 quantile across all sites and samples). In addition to the standard differential DNA methylation analysis of individual CpG sites, aggregated analyses were performed for various genomic regions defined by the gene annotation, including upstream segments, promoters, UTR5’s, exons, introns, gene bodies (i.e., the union of all exons and introns of a specific gene), and UTR3’s. For the aggregated analysis, the input was the mean counts across all the covered CpGs within the region.

**Combined Differential Gene Expression and Differential DNA Methylation Analysis**

In order to identify genes for which both gene expression and DNA methylation differed significantly between the kainic acid group and sham group, a combined analysis of differential gene expression and (aggregated = differentially methylated regions) differential DNA methylation was performed for each genomic feature. For each feature type (upstream, promoter, UTR5, exon, intron, gene body, and UTR3), only the genes surviving filters in the corresponding aggregated differential DNA methylation data set were kept and used as inputs in a new differential gene expression analysis. Co-occurrence of differential gene expression and differential DNA methylation was declared for features surviving a FDR cutoff of 25% in both analyses.

**Functional Enrichment Analysis**

Enrichment analyses of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were performed with the goana and kegga functions of edgeR, with the parameter species = “Mm”.

**Selection of Relevant Gene Ontology and Kyoto Encyclopedia of Genes and Genomes Terms**

Epileptogenesis-relevant GO and KEGG terms in neurons and glia were selected manually among the complete lists of respective terms in Supplementary Table (sheets 2, 3, 5, 6, 22, 23, 25, and 26) based on reviews on the subject (4, 15) and personal knowledge.

**RESULTS**

A systematic overview of all data is given in Figure 2.

**Quality Control**

The bisulfite conversion rates of the included samples were above 98% (Supplementary Figure 1).
plots for RRBS and mRNAseq (Supplementary Figure 2) clearly distinguished NeuN+ (referred to as neurons) and NeuN− (referred to as glia) fractions. As shown in the normalized mRNAseq plots (Supplementary Figure 3), the NeuN+ fraction was enriched for neuronal mRNA and the NeuN− fraction for glial mRNA. For further details regarding quality control of the differential gene expression and differential DNA methylation data, see Supplementary Document.

**Differential Gene Expression in the Hippocampus Contralateral to Kainate Injection**

For the analysis of differentially expressed genes, mouse hippocampi contralateral to the kainate injection site were compared to the corresponding hippocampi of sham (saline)-treated animals 24 h post-injection. Differential gene expression was measured in neurons and glia separately. In neurons, 115 genes were upregulated and 16 downregulated (ratio of upregulated to downregulated genes, 7.19) (Table 1 and Supplementary Table, sheet 1). In glia, 74 genes were upregulated and 22 downregulated (ratio of upregulated to downregulated genes, 3.36) (Table 2 and Supplementary Table, sheet 4). We found an overlap of 27 genes differentially expressed in both neurons and glia. All of these were upregulated in both cell types. Comprehensive results from the GO term analysis and KEGG pathway analysis can be found in Supplementary Table (sheets 2, 3, 5, and 6). Selected results considered relevant for epileptogenesis are listed in Table 3 for neurons and Table 4 for glia cells.

**Comparison of Differential Gene Expression Between the Contralateral and Ipsilateral Hippocampus**

Comparison of differential gene expression in CLH to ILH (22) revealed similar numbers of differentially expressed genes for neurons, while there was a marked difference in the glia. In the neuronal fraction, 115 genes were upregulated in the CLH and 115 genes were upregulated in the ILH (Supplementary Table, sheet 27). In glia, only half of the number of genes were upregulated in the CLH (74 genes; Table 1 and Supplementary Table, sheet 1) while 132 genes were upregulated in the CLH (Supplementary Table, sheet 27). Sixteen genes were downregulated in the CLH (Table 1 and Supplementary Table, sheet 1) and 15 genes downregulated in the ILH (Supplementary Table, Sheet 27). The difference was more pronounced for the downregulated genes (22 in the CLH vs. 85 in the ILH).

**Overlap of Differentially Expressed Genes in the Contralateral and Ipsilateral Hippocampus**

A comparison of genes differentially expressed in the CLH to those differentially expressed in the ILH (Supplementary Table, sheets 27 and 28) (22) revealed that a large number of differentially expressed genes coincided between CLH and ILH. This was the case both in the neurons and glia (Figure 3).
| Gene symbol | logFC | FDR  | Gene description |
|-------------|-------|------|------------------|
| Gadd45g     | 2.14  | 0.09 | Growth arrest and DNA-damage-inducible 45 gamma |
| Serinc2     | 1.99  | 0.09 | Serine incorporator 2 |
| Vgf         | 2.20  | 0.09 | VGF nerve growth factor inducible |
| Tpgb        | 1.70  | 0.09 | Trophoblast glycoprotein |
| Sulf1       | 1.39  | 0.10 | Sulfatase 1 |
| Snx1        | 1.89  | 0.10 | Sulfreldoxin 1 homolog |
| Acvr1c      | 2.22  | 0.10 | Activin A receptor, type IC |
| Timp1       | 3.26  | 0.11 | Tissue inhibitor of metalloproteinase 1 |
| Pbx3        | 3.28  | 0.11 | Pentraxin-related gene |
| Gpr3        | 1.93  | 0.11 | G-protein-coupled receptor 3 |
| Homer1      | 1.66  | 0.12 | Homer scaffolding protein 1 |
| Clec1f      | 2.67  | 0.12 | Cardiotrophin-like cytokine factor 1 |
| Cd1d2       | 3.12  | 0.12 | CD1d2 antigen |
| Pappa       | 2.35  | 0.13 | Pregnancy-associated protein A |
| C2cd4b      | 2.39  | 0.14 | C2 calcium-dependent domain containing 4B |
| Csf3        | 3.58  | 0.14 | Activating transcription factor 3 |
| Fndc9       | 2.91  | 0.14 | Fibronectin type III domain containing 9 |
| Anxa2       | 1.68  | 0.14 | Annexin A2 |
| Sbnoc2      | 1.99  | 0.16 | Strawberry notch 2 |
| Stk40       | 1.60  | 0.16 | Serine/threonine kinase 40 |
| Nfkbia      | 2.08  | 0.16 | Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, epsilon |
| Anxa2       | 2.29  | 0.17 | Annexin A2 |
| Sphk1       | 2.41  | 0.17 | Sphingosine kinase 1 |
| Serpina3n   | 1.99  | 0.17 | Serine (or cysteine) peptidase inhibitor, clade A, member 3N |
| Qfara1      | 1.63  | 0.19 | Gial glial cell derived neurotrophic factor family receptor alpha 1 |
| Rasl11a     | 1.57  | 0.19 | RAS-like, family 11, member A |
| Ier5        | 1.84  | 0.19 | Immediate early response 5 |
| Dgat2b6     | 3.38  | 0.19 | Diacylglycerol O-acetyltransferase 2-like 6 |
| Hpgd        | 1.88  | 0.19 | Hydroxyprostaglandin dehydrogenase 15 (NAD) |
| Pear1       | 3.10  | 0.19 | Platelet endothelial aggregation receptor 1 |
| Kif18a      | 1.63  | 0.20 | Kinesin family member 18A |
| Prex1       | 1.98  | 0.20 | Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 |
| Pipp4       | 1.97  | 0.20 | Phospholipid phosphatase 4 |
| Adams1s6    | 1.66  | 0.20 | A disintegrin-like and metalloproteinase (reprolysin type) with thrombospondin type 1 motif 6 |
| Dusp5       | 1.74  | 0.20 | Dual specificity phosphatase 5 |
| Col5a3      | 1.99  | 0.20 | Collagen, type V, alpha 3 |
| Tnfrsf12a   | 2.04  | 0.20 | Tumor necrosis factor receptor superfamily, member 12a |
| Ier2        | 2.09  | 0.20 | Immediate early response 2 |
| Tgfb2       | 1.52  | 0.20 | Transforming growth factor, beta receptor II |
| Ptgs1       | 2.04  | 0.20 | Prostaglandin-endoperoxide synthase 1 |
| Cad1na1     | 2.41  | 0.20 | Cyclin-dependent kinase inhibitor 1A |

Differentially expressed genes in neurons in the contralateral hippocampus (FDR < 0.25). logFC, log fold change; FDR, false discovery rate.

| Gene symbol | logFC | FDR  | Gene description |
|-------------|-------|------|------------------|
| Cgref1      | 1.67  | 0.19 | Cell growth regulator with EF hand domain 1 |
| Atr4d       | 2.01  | 0.19 | ADP-ribosylation factor-like 4D |
| Pippox      | 2.07  | 0.19 | Pipellicolic acid oxidase |
| Fos2        | 1.62  | 0.19 | Fos-like antigen 2 |
| Pik3r6       | 1.76  | 0.20 | Phosphoinositide-3-kinase regulatory subunit 5 |
| Ccn1        | 2.26  | 0.20 | Cellular communication network factor 1 |
| Ltbp1       | 1.67  | 0.20 | Latent transforming growth factor beta binding protein 1 |
| Btg2        | 1.74  | 0.20 | BTG anti-proliferation factor 2 |
| Prir         | 2.08  | 0.20 | Prolactin receptor |
| Zl3p6        | 2.22  | 0.20 | Zinc finger protein 36 |
| Efemp2      | 1.49  | 0.20 | Epidermal growth factor-containing fibulin-like extracellular matrix protein 2 |
| Rasa4       | 1.91  | 0.21 | RAS p21 protein activator 4 |
| Cd300ib      | 6.27  | 0.21 | CD300 molecule like family member B |
| Sv2c        | 2.18  | 0.21 | Synaptic vesicle glycoprotein 2C |
| Bdnf        | 1.78  | 0.21 | Brain derived neurotrophic factor |
| Medag       | 2.15  | 0.21 | Mesenteric estrogen-dependent adipogenesis |
| Mt1         | 2.12  | 0.21 | Metallothionein 1 |
| S100a10     | 1.93  | 0.21 | S100 calcium binding protein A10 |
| Npy         | 2.23  | 0.23 | Neuroptide Y |
| Notch1      | 1.80  | 0.24 | Notch 1 |
| Sstr2       | 2.15  | 0.24 | Somatostatin receptor 2 |
| Rbms1       | 1.40  | 0.24 | RNA binding motif, single-stranded interacting protein 1 |
| F2r         | 1.45  | 0.24 | Coagulation factor II (thrombin) receptor |
| Chst5       | 1.77  | 0.24 | Carbohydrate (N-acetylgalactosamine 6-O) sulfotransferase 5 |
| Msn         | 2.05  | 0.24 | Moesin |
| Mfap4       | 1.70  | 0.24 | Microfibrillar-associated protein 4 |
| Adr1a       | 1.54  | 0.25 | Adrenergic receptor, alpha 1 |
| Emp1        | 2.12  | 0.25 | Epithelial membrane protein 1 |
| Gadd45b     | 2.45  | 0.25 | Growth arrest and DNA-damage-inducible 45 beta |

Differentially expressed genes in neurons in the contralateral hippocampus (FDR < 0.25). logFC, log fold change; FDR, false discovery rate.
TABLE 2 | Differentially expressed genes in glia in the contralateral hippocampus (CLH) at 24 h after kainate-induced status epilepticus.

| Gene symbol | logFC | FDR  | Gene description |
|-------------|-------|------|------------------|
| **UPREGULATED GENES (N = 74)** |
| Socs3       | 5.55  | 0.00 | Suppressor of cytokine signaling 3 |
| Fos         | 5.82  | 0.00 | FBJ osteosarcoma oncogene |
| Serpina3n    | 4.19  | 0.00 | Serine (or cysteine) peptidase inhibitor, clade A, member 3N |
| Cebpd       | 2.82  | 0.01 | CCAAT/enhancer binding protein delta |
| Tnfrsf12a   | 3.85  | 0.01 | Tumor necrosis factor receptor superfamily, member 12a |
| **Gadd45b** | 5.36  | 0.01 | Growth arrest and DNA-damage-inducible 45 beta |
| Emp1        | 4.30  | 0.01 | Epithelial membrane protein 1 |
| Ier5l       | 2.81  | 0.02 | Immediate early response 5-like |
| S1pr3       | 3.68  | 0.01 | Sphingosine-1-phosphate receptor 3 |
| Egr1        | 4.17  | 0.01 | Early growth response 1 |
| Timp1       | 5.61  | 0.01 | Tissue inhibitor of metalloproteinase 1 |
| Egr2        | 3.11  | 0.01 | Early growth response 2 |
| **Tubb6**   | 3.24  | 0.01 | Tubulin, beta 6 class V |
| Ccd4        | 3.89  | 0.01 | CD44 antigen |
| **Gadd45g** | 3.13  | 0.02 | Growth arrest and DNA-damage-inducible 45 gamma |
| Ccd2        | 3.28  | 0.02 | Chemokine (C-C motif) ligand 2 |
| Junb        | 3.68  | 0.02 | Jun B proto-oncogene |
| Ptx3        | 5.09  | 0.02 | Pentraxin related gene |
| Fosb        | 3.92  | 0.02 | FBJ osteosarcoma oncogene B |
| Tm4sf1      | 4.35  | 0.02 | Transmembrane 4 superfamily member 1 |
| Spfhk1      | 3.78  | 0.02 | Sphingosine kinase 1 |
| Gm3448      | 2.79  | 0.02 | Predicted gene 3448 |
| Ccd12       | 4.33  | 0.02 | Chemokine (C-C motif) ligand 12 |
| Vgf         | 3.00  | 0.02 | VGF nerve growth factor inducible |
| Fst14       | 2.60  | 0.03 | Follistatin-like 4 |
| Myc         | 2.84  | 0.03 | Myelocytomatosis oncogene |
| Itga5       | 3.38  | 0.03 | Integrin alpha 5 (fibronectin receptor alpha) |
| Cebpb       | 2.35  | 0.03 | CCAAT/enhancer binding protein (C/EBP), beta |
| Arid5a      | 2.05  | 0.03 | AT rich interactive domain 5A (MRF1-like) |
| Ier3        | 2.61  | 0.04 | Immediate early response 3 |
| Thbcl       | 2.01  | 0.04 | Thrombomodulin |
| Adamts1     | 2.86  | 0.05 | A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 1 |
| **Ecm1**    | 2.09  | 0.05 | Extracellular matrix protein 1 |
| Sbnx2       | 2.62  | 0.05 | Strawberry notch 2 |
| Slc39a14    | 2.19  | 0.05 | Solute carrier family 39 member 14 |
| Hmgat1b     | 2.22  | 0.05 | High mobility group AT-hook 1B |
| Itfr1       | 1.90  | 0.06 | Interleukin 1 receptor, type I |
| Klk9        | 3.35  | 0.06 | Kallikrein related-peptidase 9 |
| **Dusp5**   | 2.25  | 0.07 | Dual specificity phosphatase 5 |
| Ucn2        | 5.70  | 0.08 | Urocortin 2 |
| Gpr151      | 3.15  | 0.08 | G protein-coupled receptor 151 |
| Ier2        | 2.71  | 0.08 | Immediate early response 2 |
| Mafk        | 2.96  | 0.08 | V-maf musculoaponeurotic fibrosarcoma oncogene family, protein K |
| **DOWNREGULATED GENES (N = 22)** |
| Cnr1        | 2.60  | 0.08 | Cysteine-serine-rich nuclear protein 1 |
| Itga7       | 1.74  | 0.09 | Integrin alpha 7 |
| Fos2        | 2.05  | 0.10 | Fos-like antigen 2 |
| Bcl3        | 5.25  | 0.10 | B cell leukemia/lymphoma 3 |
| Ait3        | 4.24  | 0.12 | Activating transcription factor 3 |
| Fosl1       | 2.36  | 0.13 | Fos-like antigen 1 |
| Hmgat1      | 2.49  | 0.13 | High mobility group AT-hook 1 |
| Lox1        | 2.05  | 0.13 | Lysyl oxidase-like 1 |
| Mchr1       | 2.23  | 0.13 | Melanin-concentrating hormone receptor 1 |
| Kdm6b       | 1.71  | 0.13 | KDM1 lysine (K)-specific demethylase 6B |
| Odc1        | 1.90  | 0.13 | Ornithine decarboxylase, structural 1 |
| Cdk24a      | 2.96  | 0.13 | CD244 molecule A |
| Mr1         | 3.59  | 0.15 | Macrophage scavenger receptor 1 |
| Sv2c        | 2.70  | 0.15 | Sypathetic vesicle glycoprotein 2c |
| Tma16       | 1.82  | 0.16 | Translation machinery associated 16 |
| C2cd4b      | 2.69  | 0.16 | C2 calcium-dependent domain containing 4B |
| Egr4        | 2.41  | 0.16 | Early growth response 4 |
| Hspb1       | 3.46  | 0.17 | Heat shock protein 1 |
| Tnc         | 1.67  | 0.17 | Tenascin C |
| Sxnr1       | 1.92  | 0.17 | Sulfiredoxin 1 homolog |
| Ahnak2      | 2.75  | 0.17 | AHNAK nucleoprotein 2 |
| Wwtr1       | 1.64  | 0.17 | WW domain containing transcription regulator 1 |
| Gpr3        | 2.00  | 0.18 | G-protein coupled receptor 3 |
| Zfp36       | 2.57  | 0.18 | Zinc finger protein 36 |
| Trib1       | 1.95  | 0.18 | Tribbles pseudokinase 1 |
| Il11        | 2.88  | 0.21 | Interleukin 11 |
| Rhoj        | 2.62  | 0.21 | Ras homolog family member J |
| Hcar2       | 3.17  | 0.21 | Hydroxycarboxylic acid receptor 2 |
| Cdh22       | 2.02  | 0.24 | Cadherin 22 |
| Pvr         | 1.49  | 0.25 | Poliovirus receptor |
| Slc7a1      | 1.23  | 0.25 | Solute carrier family 7 member 1 |
| **SUSPENDED GENES (N = 148)** |
| (Continued)  |
| (Continued)  |
### TABLE 2 | Continued

| Gene symbol | logFC | FDR  | Gene description                              |
|-------------|-------|------|-----------------------------------------------|
| Maf         | −1.49 | 0.17 | Avian musculoaponeurotic fibrosarcoma oncogene homolog |
| Fn3k        | −1.87 | 0.17 | Fructosamine 3 kinase                          |
| Tmem255b    | −2.02 | 0.17 | Transmembrane protein 255B                     |
| Traf4       | −1.75 | 0.17 | TNF receptor associated factor 4               |
| Fam228a     | −1.73 | 0.17 | Family with sequence similarity 228, member A   |
| Pqcr7       | −1.94 | 0.20 | Progestin and adipocytokine receptor family member VII |
| Gpr34       | −2.49 | 0.21 | G protein-coupled receptor 34                   |
| Sowaha      | −1.46 | 0.21 | Sosondowah ankyrin repeat domain family member A |
| Phkg1       | −1.77 | 0.25 | Phosphorylase kinase gamma 1                    |
| Foh1        | −2.08 | 0.25 | Folate hydrolase 1                             |

Differentially expressed genes in glia in the contralateral hippocampus (FDR < 0.25).

### TABLE 3 | Selection of relevant Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) terms of the differentially expressed genes in neurons in the contralateral hippocampus (CLH) at 24 h after kainate-induced status epilepticus.

| GO                                      | Upregulated in neurons (115 genes) | Downregulated in neurons (16 genes) |
|-----------------------------------------|-----------------------------------|------------------------------------|
| Cell death                              | Positive regulation of calcium ion transport |                                  |
| Regulation of cell proliferation        | Axon guidance                      |                                    |
| Cell communication                      | Vesicle organization               |                                    |
| MAPK cascade                            | Regulation of DNA-binding transcription factor activity |                                  |
| Cell surface receptor signaling pathway | Axonogenesis                        |                                    |
| Regulation of transcription, DNA-templated | Growth factor activity             |                                    |
| Vasculature development                 | Programmed cell death              |                                    |
| Inflammatory response                   | Blood vessel morphogenesis          |                                    |

| KEGG                                    |                                   |                                    |
|-----------------------------------------|-----------------------------------|------------------------------------|
| Cytokine-cytokine receptor interaction  | Axon guidance                      |                                   |
| cAMP signaling pathway                  | NF-kappa B signaling pathway       |                                   |
| ECM–receptor interaction                | Leukocyte transendothelial migration |                            |
| IL-17 signaling pathway                 | –                                 |                                    |
| TGF-baka signaling pathway              | –                                 |                                    |
| TNF signaling pathway                   | –                                 |                                    |
| MAPK signaling pathway                  | –                                 |                                    |
| p53 signaling pathway                   | –                                 |                                    |
| VEGF signaling pathway                  | –                                 |                                    |
| JAK-STAT signaling pathway              | –                                 |                                    |

### TABLE 4 | Selection of relevant Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) terms of the differentially expressed genes in glia in the contralateral hippocampus (CLH) at 24 h after kainate-induced status epilepticus.

| GO                                      | Upregulated in glia (74 genes) | Downregulated in glia (22 genes) |
|-----------------------------------------|---------------------------------|-----------------------------------|
| Regulation of angiogenesis              | G protein-coupled nucleotide receptor activity |                                  |
| Regulation of cell motility             | Purinergic receptor activity    |                                    |
| Positive regulation of cell migration   | Oxidation-reduction process     |                                    |
| Positive regulation of cell death       | –                               |                                    |
| Angiogenesis                            | –                               |                                    |
| Regulation of interleukin-1 beta        | Production                      |                                    |
| Tumor necrosis factor production        | –                               |                                    |
| Neurogenesis                            | –                               |                                    |

**For neurons, 77 upregulated genes and eight downregulated genes were differentially expressed in both the CLH and ILH (Figure 3 and Supplementary Table, sheets 1 and 27). This constitutes a proportion of 65.22% (up) and 50.00% (down) of all the differentially regulated genes in the CLH. For glia, we found an overlap of 55 upregulated genes and an overlap of 17 downregulated genes between the CLH and ILH (Figure 3 and Supplementary Table, sheets 4 and 28). This translates to a proportion of 74.32% (up) and 77.27% (down) of all the differentially regulated genes in the CLH. All overlapping genes between the CLH and ILH showed concordant expression.**

**Genes Exclusively Differentially Expressed in the Ipsilateral Hippocampus**

In neurons, we found 55 genes to be upregulated and seven downregulated genes to be upregulated exclusively in the ILH (Table 5 and Supplementary Table, sheet 21). In glia, 92 genes were upregulated and 68 genes were downregulated exclusively in the ILH (Table 6 and Supplementary Table, sheet 24). The relevant GO and KEGG terms of these differentially expressed genes are listed in Tables 7 and 8, and a detailed list of the GO and KEGG terms is to be found in Supplementary Table (sheets 22, 23, 25, and 26).
Differential Methylation in the Hippocampus Contralateral to Kainate Injection

Differentially methylated CpGs were analyzed comparing left (contralateral) hippocampi of the kainic acid group to the sham group at 24 h after status epilepticus induction. For an overview of the number and distribution of the differentially methylated sites and the differentially methylated regions, see Figure 4. For a detailed list of the differentially methylated CpGs, differentially methylated regions, and the associated GO and KEGG terms, see Supplementary Table (differentially methylated CpGs: sheets 7 and 10; differentially methylated regions: sheets 13 and 16; differentially methylated CpGs GO: sheets 8 and 11; differentially methylated CpGs KEGG: sheets 9 and 12; differentially methylated regions GO: sheets 14 and 17; differentially methylated regions KEGG: sheets 15 and 18).

Overlap of Differentially Methylated CpGs Between Neurons and Glia

Ten CpG sites (0.12% of all differentially methylated CpGs in the CLH) were hypermethylated and six CpG sites (0.09%) hypomethylated in both neurons and glia. Twenty-one CpGs (0.18%) were hypermethylated in neurons and hypomethylated in glia and 13 hypomethylated in neurons and hypermethylated in glia (0.18%).

Association Between Differential Methylation and Differential Gene Expression in the Contralateral Hippocampus

In order to investigate a possible statistical association between differential DNA methylation and differential gene expression in the CLH, significantly differentially methylated regions and differentially expressed genes were aligned. No general trend in the association between the differentially methylated regions (upstream, promoter, UTR5, exon, intron, gene body, and UTR3) and differential gene expression was found (see figures in Supplementary Table, sheets 19 and 20), but significant alterations in DNA methylation and gene expression coincided at 11 genomic loci for neurons and four genomic loci for glia (Supplementary Table, sheets 19 and 20).
TABLE 5 | Differentially expressed genes in neurons exclusively in the ILH (and not the CLH) at 24 h after kainate-induced status epilepticus.

| Gene symbol | logFC.ILH | FDR.ILH | Gene description |
|-------------|-----------|---------|-----------------|
| Hspa1a      | 5.46      | 0.01    | Heat shock protein 1A |
| Mapk4       | 2.28      | 0.01    | Mitogen-activated protein kinase 4 |
| Hspa1b      | 4.82      | 0.02    | Heat shock protein 1B |
| Pcdh11x     | 2.26      | 0.03    | Protocadherin 11 X-linked |
| Pde6b       | 2.91      | 0.03    | Phosphodiesterase 6B, cGMP, rod receptor, beta polypeptide |
| Wisp1       | 2.09      | 0.03    | WNT1-inducible-signaling pathway protein 1 |
| 9330188P03Rik| 3.35      | 0.03    | RIKEN cDNA 9330188P03 gene |
| Hspb1       | 4.00      | 0.03    | Heat shock protein 1 |
| Lbh         | 3.01      | 0.03    | Limb-bud and heart |
| Prad        | 4.89      | 0.04    | Ras-related associated with diabetes |
| 4931440P22Rik| 1.70      | 0.04    | RIKEN cDNA 4931440P22 gene |
| Cyr61       | 2.90      | 0.04    | Cysteine-rich angiogenic inducer 61 |
| Zbtb46      | 1.58      | 0.05    | Zinc finger and BTB domain containing 46 |
| Bac1        | 1.72      | 0.05    | BTB and CNC homology 1, basic leucine zipper transcription factor 1 |
| Samd4       | 1.90      | 0.05    | Sterile alpha motif domain containing 4 |
| Npas4       | 3.24      | 0.06    | Neuronal PAS domain protein 4 |
| Adam19      | 1.62      | 0.08    | A disintegrin and metallopeptidase domain 19 (meltrin beta) |
| Pim1        | 2.43      | 0.08    | Proviral integration site 1 |
| Mapkapk3    | 1.97      | 0.09    | Mitogen-activated protein kinase-activated protein kinase 3 |
| Cdh4        | 1.45      | 0.09    | Cadherin 4 |
| Kdm6b       | 1.57      | 0.09    | KDM1 lysine (K)-specific demethylase 6B |
| Spp1        | 3.14      | 0.09    | Secreted phosphoprotein 1 |
| Sorcs3      | 2.28      | 0.09    | Sortilin-related VPS10 domain containing receptor 3 |
| Uck2        | 1.35      | 0.10    | Uridine-cytidine kinase 2 |
| Pice1       | 1.40      | 0.10    | Phospholipase C, epsilon 1 |
| Tgif1/1     | 1.66      | 0.10    | Transforming growth factor beta-1-induced transcript 1 |
| Frrs1       | 1.87      | 0.12    | Ferric-chelate reductase 1 |
| Blink       | 2.81      | 0.12    | B cell linker |
| Rgs20       | 1.74      | 0.12    | Regulator of G-protein signaling 20 |
| Itpkr       | 1.88      | 0.13    | Inositol 1,4,5-trisphosphate receptor interacting protein |
| Smad7       | 1.83      | 0.13    | SMAD family member 7 |
| Svl         | 1.52      | 0.13    | Supervillin |
| Mir132      | 3.39      | 0.15    | MicroRNA 132 |
| Zdhhc22     | 1.85      | 0.17    | Zinc finger, DHHC-type containing 22 |
| Amot1i      | 1.71      | 0.18    | Angiomotin-like 1 |
| Serpina3i   | 2.75      | 0.18    | Serine (or cysteine) peptidase inhibitor, clade A, member 3i |
| Itf1        | 2.33      | 0.18    | Interferon-induced protein with tetratricopeptide repeats 1 |

**UPREGULATED GENES (N = 55; ILH: 132)**

**DOWNREGULATED GENES (N = 7; ILH: 15)**

**TABLE 5 | Continued**

| Gene symbol | logFC.ILH | FDR.ILH | Gene description |
|-------------|-----------|---------|-----------------|
| Kcnip3      | 1.67      | 0.18    | Kv channel interacting protein 3, catenin |
| Odc1        | 1.57      | 0.18    | Ornithine decarboxylase, structural 1 |
| Igf9b       | 2.27      | 0.18    | Immunoglobulin superfamily, member 9B |
| Sprend1     | 1.62      | 0.18    | Sprouty protein with EVH-1 domain 1, related sequence |
| Samd11      | 2.19      | 0.19    | Sterile alpha motif domain containing 11 |
| Scd4        | 2.01      | 0.19    | Stearoyl-coenzyme A desaturase 4 |
| Dusp4       | 1.88      | 0.19    | Dual specificity phosphatase 4 |
| Tisparr9     | 1.68      | 0.19    | Tetraspanin 9 |
| Eva1b       | 2.00      | 0.19    | Eva-1 homolog B (C. elegans) |
| Btc         | 2.40      | 0.19    | Betacellulin, epidermal growth factor family member |
| St8sia2     | 2.11      | 0.20    | STB alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 |
| Tm4sf1      | 2.49      | 0.20    | Transmembrane 4 superfamily member 1 |
| Cdt22       | 1.77      | 0.20    | Cadherin 22 |
| Itgalpha    | 2.11      | 0.21    | Integrin alpha 5 (fibroblast receptor alpha) |
| Mapk6       | 1.51      | 0.22    | Mitogen-activated protein kinase 6 |
| Eg4         | 1.91      | 0.23    | Early growth response 4 |
| Itpkc       | 1.84      | 0.23    | Inositol 1,4,5-trisphosphate 3-kinase C |
| Drd1        | 1.82      | 0.25    | Dopamine receptor D1 |
| Echodc2     | −1.77     | 0.08    | Enoyl coenzyme A hydratase domain containing 2 |
| Cyp7b1      | −2.28     | 0.10    | Cytochrome P450, family 7, subfamily b, polypeptide 1 |
| Gstm6       | −1.57     | 0.16    | Glutathione S-transferase, mu 6 |
| Crf1        | −1.97     | 0.19    | Cytokine receptor-like factor 1 |
| Macrod1     | −1.53     | 0.20    | MACRO domain containing 1 |
| Gm35339     | −1.43     | 0.20    | Predicted gene, 35339 |
| 6330420H09Rik| −2.15     | 0.22    | RIKEN cDNA 6330420H09 gene |

**Differential DNA Methylation, and Association of Differential Methylation With Differential Gene Expression, in the Contralateral Hippocampus Compared With the Ipsilateral Hippocampus**

Only a fragment of the differentially methylated CpGs and the differentially methylated regions overlapped between the CLH and ILH (22). Of all the differentially methylated CpGs in neurons in the CLH, 48 (0.44% of all the differentially methylated
### TABLE 6
Differentially expressed genes in glia exclusively in the ILH (and not CLH) at 24 h after kainate-induced status epilepticus.

| Gene symbol | logFC.ILH | FDR.ILH | Gene description |
|-------------|-----------|---------|------------------|
| **UPREGULATED GENES** (**N** = 92; **ILH**: 147) | | | |
| Ch25h       | 5.14      | 0.00    | Cholesterol 25-hydroxylase |
| Lir4b       | 4.88      | 0.00    | Leukocyte immunoglobulin-like receptor, subfamily B, member 4B |
| Calca       | 4.68      | 0.01    | Calcitonin/calcitonin-related polypeptide, alpha |
| Spp1        | 4.71      | 0.01    | Secreted phosphoprotein 1 |
| Fn1         | 2.64      | 0.01    | Fibronectin 1 |
| Fg2         | 2.97      | 0.01    | Fibrinogen-like protein 2 |
| Rasgef1c    | 3.04      | 0.01    | RasGEF domain family, member 1C |
| Ifit3       | 2.69      | 0.01    | Interferon-induced protein with tetratricopeptide repeats 3 |
| Igf1p       | 3.09      | 0.02    | Interferon inducible GTPase 1 |
| Rasl11a     | 1.99      | 0.02    | RAS-like, family 11, member A |
| Btc         | 3.29      | 0.02    | Betacellulin, epidermal growth factor family member |
| Nptx2       | 2.91      | 0.03    | Neuronal pentraxin 2 |
| Adam8       | 3.04      | 0.03    | A disintegrin and metallopeptidase domain 8 |
| Inhba       | 2.61      | 0.03    | Inhibin beta-A |
| Lirb4a      | 4.02      | 0.03    | Leukocyte immunoglobulin-like receptor, subfamily B, member 4A |
| Cd300lf     | 3.60      | 0.03    | CD300 molecule like family member F |
| Cacng6      | 2.10      | 0.03    | Calcium channel, voltage-dependent, gamma subunit 5 |
| Ifi204      | 4.09      | 0.03    | Interferon activated gene 204 |
| Dab2        | 2.15      | 0.04    | Disabled 2, mitogen-responsive phosphoprotein |
| Ifi207      | 3.11      | 0.04    | Interferon activated gene 207 |
| Parp3       | 2.74      | 0.04    | Poly(ADP-ribose) polymerase family, member 3 |
| Rasip1      | 2.30      | 0.05    | Ras interacting protein 1 |
| Lpl         | 1.88      | 0.06    | Lipoprotein Ipase |
| Tpbg        | 1.72      | 0.06    | Trophoblast glycoprotein |
| Gcnt2       | 2.42      | 0.06    | Glucosaminyl (N-acetyl)transferase 2, L-branchoing enzyme |
| Serpine1    | 3.97      | 0.06    | Serine (or cysteine) peptidase inhibitor, clade E, member 1 |
| Oas1        | 2.47      | 0.07    | 2'-5' Oligoadenylate synthetase-like 2 |
| Ptgs2       | 2.43      | 0.07    | Prostaglandin-endoperoxide synthase 2 |
| Slc10a6     | 3.88      | 0.07    | Solute carrier family 10 (sodium/bile acid cotransporter family), member 6 |
| Ahnak       | 1.95      | 0.07    | AHNAK nucleoprotein (desmoyokin) |
| Neddf9      | 1.33      | 0.07    | Neural precursor cell expressed, developmentally downregulated gene 9 |
| Rai14       | 1.61      | 0.07    | Retinoic acid induced 14 |
| Layn        | 1.95      | 0.08    | Laylin |
| Col16a1     | 2.51      | 0.08    | Collagen, type XVI, alpha 1 |
| Atp10a      | 2.07      | 0.08    | ATPase, class V, type 10A |
| Gai         | 3.44      | 0.08    | Galanin and GMAP prepropeptide |
| **CONTINUED** | | | |

**Continued**
| Gene symbol | logFC.ILH | FDR.ILH | Gene description |
|-------------|-----------|---------|------------------|
| Itga2b      | 1.93      | 0.20    | Integulin alpha 2b |
| Fgfr4       | 2.25      | 0.20    | Fibroblast growth factor receptor 4 |
| Bst2        | 2.06      | 0.20    | Bone marrow stromal cell antigen 2 |
| Gm6225      | 2.35      | 0.21    | Predicted gene 6225 |
| Cb1n4       | 1.60      | 0.21    | Cerebellin 4 precursor protein |
| Serpin3m    | 2.79      | 0.22    | Serine (or cysteine) peptidase inhibitor, clade A, member 3M |
| Akap12      | 1.34      | 0.22    | A kinase (PRKA) anchor protein (gravin) 12 |
| Sdc1        | 1.59      | 0.22    | Syndecan 1 |
| Ndst1       | 1.59      | 0.22    | N-deacetylase/N-sulfotransferase (heparan glucosaminy1) 1 |
| Npas4       | 2.45      | 0.22    | Neuronal PAS domain protein 4 |
| Tspan4      | 1.89      | 0.23    | Tetraspanin 4 |
| Klk6        | 2.76      | 0.23    | Kallikrein related-peptidase 6 |
| Cxcl10      | 2.90      | 0.23    | Chemokine (C-X-C motif) ligand 10 |
| Col7a1      | 1.75      | 0.23    | Collagen, type VII, alpha 1 |
| Ppck1       | 1.17      | 0.24    | Phosphokinas C, epsilon 1 |
| Peak1       | 1.41      | 0.24    | Pseudosperm enriched atypical kinase 1 |
| Itga1       | 1.36      | 0.25    | Integulin alpha 1 |

**DOWNREGULATED GENES (N = 68; ILH: 85)**

| Gene symbol | logFC.ILH | FDR.ILH | Gene description |
|-------------|-----------|---------|------------------|
| Pcx         | −2.11     | 0.02    | Pyruvate carboxylase |
| Shroom2     | −2.28     | 0.03    | Shroom family member 2 |
| Gpr12       | −2.22     | 0.04    | G-protein-coupled receptor 12 |
| Ccdc13      | −1.80     | 0.05    | Coiled-coil domain containing 13 |
| Cygb        | −1.88     | 0.05    | Cytoglobin |
| Ankub1      | −2.23     | 0.06    | Ankyrin repeat and ubiquitin domain containing 1 |
| Siglech     | −2.16     | 0.06    | Sialic acid binding Ig-like lectin H |
| Itpka       | −1.70     | 0.06    | Inositol 1,4,5-trisphosphate 3-kinase A |
| Hhcpa       | −1.84     | 0.07    | Hipoccalcin |
| Ppp1r1b     | −1.75     | 0.08    | Protein phosphatase 1, regulatory inhibitor subunit 1B |
| Nkain4      | −2.55     | 0.08    | Na+/K+ transporting ATPase interacting 4 |
| Kctd4       | −2.09     | 0.08    | Potassium channel tetramerization domain containing 4 |
| Gstm6       | −1.67     | 0.08    | Glutathione S-transferase, mu 6 |
| Shisa8      | −2.21     | 0.09    | Shisa family member 8 |
| 2810468N07Rk| −2.22     | 0.09    | RIKEN cDNA 2810468N07 gene |
| Abca9       | −1.97     | 0.09    | ATP-binding cassette, sub-family A (ABC1), member 9 |
| Chn1        | −1.71     | 0.10    | Chimerin 1 |
| Ntar2       | −2.14     | 0.11    | Neurotransin receptor 2 |
| Myh14       | −1.76     | 0.11    | Myosin, heavy polypeptide 14 |
| Fam234a     | −1.77     | 0.11    | Family with sequence similarity 234, member A |
| Faah        | −1.50     | 0.12    | Fatty acid amidohydrolase |
| Tppp3       | −1.76     | 0.12    | Tubulin polymerization-promoting protein family member 3 |

**TABLE 6 | Continued**

| Gene symbol | logFC.ILH | FDR.ILH | Gene description |
|-------------|-----------|---------|------------------|
| Abca6       | −1.46     | 0.12    | ATP-binding cassette, sub-family A (ABC1), member 6 |
| Gna1        | −1.90     | 0.13    | Guanine nucleotide binding protein (G protein), alpha inhibiting 1 |
| Cfap100     | −1.48     | 0.14    | Cilia and flagella associated protein 100 |
| Grm3        | −2.01     | 0.14    | Glutamate receptor, metabotropic 3 |
| Phgdh       | −1.66     | 0.15    | 3-Phosphoglycerate dehydrogenase |
| Seplg       | −2.14     | 0.15    | Selectin, platelet (p-selectin) ligand |
| Epn2        | −1.61     | 0.17    | Epsin 2 |
| Rlbp1       | −1.78     | 0.18    | Retinaldehyde binding protein 1 |
| Pantr1      | −1.72     | 0.18    | POU domain, class 3, transcription factor 3 adjacent non-coding transcript 1 |
| Plk5        | −2.14     | 0.18    | Polo-like kinase 5 |
| Nat8f1      | −1.91     | 0.18    | N-acetyltransferase 8 (GCNS-related) family member 1 |
| 1700066M21Rk| −1.65     | 0.18    | RIKEN cDNA 1700066M21 gene |
| Ad1         | −1.61     | 0.18    | Acriducence dioxygenase 1 |
| Tnem191c    | −1.45     | 0.18    | Transmembrane protein 191C |
| Gmnc        | −2.55     | 0.18    | Geminin coiled-coil domain containing 1 |
| Zfp763      | −1.51     | 0.18    | Zinc finger protein 763 |
| Slc25a18    | −1.79     | 0.19    | Solute carrier family 25 (mitochondrial carrier), member 18 |
| Hhip        | −2.01     | 0.19    | Hedgehog-interacting protein |
| Calb1       | −1.51     | 0.19    | Calbindin 1 |
| Chn1        | −1.74     | 0.19    | Carbohydrate (N-acetylglucosamine 6-C) sulfotransferase 5 |
| Trim59      | −2.18     | 0.19    | Tripartite motif-containing 59 |
| Olfr101     | −2.24     | 0.19    | Olfactomedin-like 1 |
| Mturn       | −1.41     | 0.19    | Maturin, neural progenitor differentiation regulator homolog (Xenopus) |
| Gstm1       | −1.80     | 0.19    | Glutathione S-transferase, mu 1 |
| Enho        | −1.63     | 0.19    | Energy homeostasis associated |
| Prodh       | −1.86     | 0.19    | Proline dehydrogenase |
| Slc27a1     | −1.71     | 0.19    | Solute carrier family 27 (fatty acid transporter), member 1 |
| Pacsin3     | −1.44     | 0.19    | Protein kinase C and casein kinase substrate in neurons 3 |
| Htr1a       | −1.95     | 0.19    | 5-Hydroxytryptamine (serotonin) receptor 1A |
| Dl3         | −1.72     | 0.19    | Delta-like canonical Notch ligand 3 |
| Map6d1      | −1.60     | 0.19    | MAP6 domain containing 1 |
| Prrg1       | −1.61     | 0.19    | Proline-rich Gia (G-carboxyglutamic acid) 1 |
| Carns1      | −1.88     | 0.20    | Carnosine synthase 1 |
| Tie2        | −1.48     | 0.20    | Transducin-like enhancer of split 2 |
| Macrod1     | −1.45     | 0.20    | MACRO domain containing 1 |
| Ngrn        | −1.51     | 0.20    | Neurogranin |
| Pln3        | −2.18     | 0.21    | Perilipin 3 |
| Grhpr       | −1.38     | 0.21    | Glyoxylate reductase/hydroxybutyrate reductase |

(Continued)
CpGs in neurons) were also differentially methylated in neurons in the ILH (22 hypermethylated and 26 hypomethylated). Regarding differentially methylated regions, 17 were overlapping between the ILH and CLH in neurons (16 hypermethylated and one hypomethylated) and two (both hypermethylated) in glia. Some of these overlapping differentially methylated CpGs and differentially methylated regions were linked to genes with epilepsy- and DNA methylation-relevant functions like TGF-beta signaling, DNA methyltransferase activity, or angiogenesis, but none of these overlapped with the differentially expressed genes in the ipsilateral or contralateral hippocampus (Supplementary Table).

Only one gene, Spp1, had an association between differential DNA methylation and differential gene expression in both the CLH and ILH (neurons). Spp1 was upregulated in both CLH and ILH. This coincided with upstream and promoter hypermethylations in the CLH and upstream and promoter hypomethylation in the ILH. No overlaps for differential DNA methylation and differential gene expression associations were found for glia when comparing CLH to ILH (Supplementary Table) (22).

**DISCUSSION**

In this study, we investigate alterations in gene expression and DNA methylation in glia and neurons in mouse hippocampi contralateral to intracortical kainic acid application. We found
fulminating changes of both the gene expression and DNA methylation in glia and neurons in the CLH at 24 h after kainate-induced status epilepticus.

Based on our findings, we will discuss possible beneficial and detrimental responses to epileptic activity in the CLH. We will further illuminate potential genetic targets relevant to hippocampal sclerosis by comparing alterations in gene expression in the CLH to gene expression in the ILH. Lastly, we will discuss DNA methylation and its role for gene expression regulation in early epileptogenesis.

**Differential Gene Expression in the Contralateral Hippocampus Only Exposed to Epileptic Activity**

We found that differential gene expression in the contralateral hippocampus at 24 h after kainate-induced status epilepticus mainly occurs cell-specific, with only a minor overlap of genes differentially expressed in the neurons and glia. This may reflect the complementary characteristic of neuron–glia interactions in epilepsy (4) and is comparable to our previous findings from cell-specific gene expression in the ipsilateral hippocampus (22).

In the CLH, the primary factor affecting differential gene expression is related to epileptic activity upon status epilepticus (Figure 1) (11). Differentially expressed genes comprise diverse inflammatory responses, synaptic signaling, and DNA methylation machinery in both neurons and glia (Tables 3, 4). Many of the gene expression changes seen in the CLH (lacking hippocampal sclerosis) overlap with our previous findings from the ILH [comprising hippocampal sclerosis at chronic time points: Supplementary Table 27 and 28 (22)]. This may appear unexpected since the CLH does not show morphological changes as seen in the ILH like reactive gliosis and neuronal death. A previous study on the ipsilateral and contralateral gene expression changes in a unilateral kainic acid epilepsy model also found a large overlap of the differentially expressed genes in the ipsilateral and contralateral hippocampus (43). The authors created different subsets of genes in order to distinguish between the effect of the kainic acid-induced lesion and epileptic seizures. A comparison of our data obtained at an early time point of epileptogenesis from the CLH to these results at a chronic stage of epileptogenesis reveals several genes overlapping with the “seizure” gene set (neurons: *Gal, Fos, Parp3, Ned9, Mfap4, Dusp5, Col27a1, Sdc1, Ptgs1*, and *Arc*; glia: *Tubb6, Fos, Ecm1*, and *Dusp5*).

We further find a great degree of overlap between the gene expression changes seen in the CLH with other studies of various animal models for epilepsy (29, 44), gene expression material from the resected hippocampi of temporal lobe epilepsy (TLE) patients (45), and even with genomic data from animal models of reactive gliosis (46).
If the gene expression response in the CLH is so similar to both the ILH (with morphological alterations such as neuronal cell death and reactive gliosis 3 months after status epilepticus initiation or earlier) (11) and diverse models of epilepsy and reactive gliosis, why does the CLH not develop comparable morphological changes? The question whether epileptic activity can lead to morphological changes has long been a matter of controversial debate and is, to date, unanswered. While several previous studies claim that seizures mediate epileptogenic effects (47, 48), others postulate that seizures per se do not promote epileptogenesis (35, 49).

A hypothesis as to why the CLH remains free of hippocampal sclerosis may be that it is exposed to fewer detrimental or a larger number of beneficial effects, or both. As for fewer detrimental effects, one apparent characteristic in the CLH is the significantly lower number of glial genes up- and downregulated compared to the ILH. Only half the number of genes are up- and only a quarter of the number of genes are downregulated compared to the ILH. With several glial genes coding for pro-inflammatory pathways (Supplementary Table, sheets 4–6), this less pronounced glial activation in the contralateral hippocampus may be related to the lack of morphological changes characteristically observed at later time points. With regard to the gene expression changes with possible beneficial effects in the CLH, we find several seizure-alleviating and even potential anti-epileptic genes and pathways upregulated. Within the glial genes in the CLH, more genes overlapped with a gene set previously related to a “beneficial” type of astrocyte (A2) than with the gene set of “detrimental” astrocytes (A1) (46), possibly representing a glia-mediated endogenic anti-epileptogenic process in early epileptogenesis. Other epileptic activity-induced genes with seizure-alleloving or potentially even anti-epileptogenic effects include Gal, Soc3, and NPY. GAL (galanin) has previously been shown to exhibit anti-seizure effects and comprises potential anti-epileptogenic qualities (50). The gene expression levels of Galanin are elevated in neurons in the CLH, possibly revealing epileptic activity-related homeostatic effects. Further, we find the gene expression levels of NPY (neuropeptide Y), a neuropeptide recently successfully shown to attenuate seizures in slices of medication-refractory TLE (51), elevated in neurons in the CLH. Lastly, we find elevated levels of SOCS3 in glia in the CLH. Soc3 codes for the suppressor of cytokine signaling 3 protein. This protein reduces the pro-inflammatory responses of, among others, IL-6, IFN, IL2, II12, and NkR signaling pathways and reduces astrocytic chemokine production (52). Thus, Soc3 expression potentially represents another example of an endogenic reaction aiming at reducing the detrimental effects of seizures.

In sum, we speculate that anti-epileptogenic effects may outweigh pro-epileptogenic effects and thus prevent morphological alterations like neuronal death and reactive gliosis in the CLH. In fact, we find a higher fraction of GO terms anticipating anti-epileptogenic effects like “neurogenesis” (glia) and a lower number of GO terms indicating pro-epileptogenic qualities like “negative regulation of neuronal death” (neurons) in the CLH (Supplementary Table, sheets 2 and 5) compared to the ILH (22).

Potential Upstream Targets of Hippocampal Sclerosis and Epileptogenesis

If one were to speculate which genes in our ipsilateral and contralateral findings in early epileptogenesis were most likely potential candidate genes driving hippocampal sclerosis and epileptogenesis, one could hypothesize that these would have to be exclusively found on the list of differentially expressed genes in the ILH. Featuring morphological changes like reactive gliosis and neuronal death, the ILH is associated with epileptogenesis (Figure 1).

For neurons, genes only differentially expressed in the ILH comprise pathways within various inflammatory responses and epilepsy-relevant genes like Mir132 (53) and Drd1 (54) (Table 5 and Supplementary Table, sheet 21). In glia, genes upregulated in the ILH but not in the CLH include several interferon- and interleukin-associated genes like Ifi13, Ibg1, Ifi204, and If4ra, other inflammatory genes previously associated with epilepsy like Ptgs2 (Cox2) (55), and epilepsy-related genes like Bdnf (56) and Mir132 (53) (Table 6 and Supplementary Table, sheet 24). Downregulated genes in glia involve, among others, Grm3, a gene encoding for the metabotropic glutamate receptor 3, previously shown to be downregulated in experimental and human mTLE (57).

Within these genes exclusively differentially expressed in the ILH (and not CLH), one could check for overlaps with the top target genes in the reactive gliosis gene set mentioned earlier. Glial Cxcl10 and Ptgs2 (Cox2) are exclusively differentially expressed in both the ILH (22) and in a previous genomic analysis of reactive gliosis (46). CXCL10, a chemokine elevated in various central nervous system (CNS) pathologies like Alzheimer’s disease (58), multiple sclerosis (59), and Rasmussen encephalitis (60), has been shown to elicit elevated neuronal excitability after acute (61) and chronic exposure (62). Produced in astrocytes (63), it mediates neuronal death via Ca2+-dependent apoptosis (64). Ptgs2, coding for COX2, a cyclooxygenase exerting pro-epileptogenic effects in epileptogenesis (55), represents another potential glial upstream target for anti-epileptogenic intervention. These findings are in line with previous studies on the importance of glia-driven inflammatory pathways in epileptogenesis (4, 65).

As mentioned, the number of genes differentially expressed by the glia in the ILH are significantly higher than those in the CLH. This possibly indicates a more pronounced glial reaction triggered by the combination of epileptic activity and kainate in the ILH. This is supported by the notion of previously reported glial responses to kainic acid injection (66). In the intracortical model of mTLE-HS, the effects of epileptic activity and kainate are difficult to disentangle. Both kainate (67–69) and epileptic activity (47, 48, 70) can exert cytotoxic effects that, in combination, might be potentiated (71, 72). A previous genomic analysis of the ipsilateral and contralateral hippocampi of kainate-injected rats in chronic epilepsy (43) created a “kainic acid” gene set—a list of genes presumably induced by kainic acid. We find a surprisingly small overlap of these “kainic acid genes” with our data (exclusively ILH: Spp1 and Hspb1 in neurons and...
Spp1 in the glia), possibly indicating that the singular effect of kainate may not be of primordial importance for downstream effects like hippocampal sclerosis and epileptogenesis after all (for restrictions in interpretability, see Limitations). Further, our goal was to identify upstream gene expression alterations possibly leading to hippocampal sclerosis, and as such, the exact cause of these alterations may be of secondary importance as long as they lead to epileptogenesis-relevant hallmarks.

DNA Methylation and Its Role for Gene Expression in Early Epileptogenesis

In line with previous studies (22, 73, 74), DNA methylation occurs mainly in a cell-specific manner in the CLH. Regarding the methylation of singular CpG sites, hypermethylation slightly outweighs hypomethylation in both neurons and glia, both with regards to differentially methylated CpGs in total and differentially methylated CpGs within genomic regions. This trend is similar to the DNA methylation dynamics observed at 24 h in the ILH (22) and to previous data from DNA methylation alterations in a rat model of chronic epilepsy (75). Differentially methylated regions were mostly hypermethylated in neurons and hypomethylated in glia. This represents a near inversion of the methylation pattern of the differentially methylated regions in the ILH, where most differentially methylated regions in neurons were hypomethylated and most differentially methylated regions in the glia were hypermethylated (22). Previous studies of epilepsy-related DNA methylation in acute phases of epilepsy in animal models found no general trend toward hyper- or hypomethylation (30) or a tendency toward hypomethylation (76).

One possible reason for the higher ratio of hypomethylated differentially methylated regions in glia in the CLH is the higher levels of gene expression of Gadd 45b and Gadd 45g, which both are capable of DNA demethylation (77). In the CLH, significant alterations of differential DNA methylation and differential gene expression coincided at several genomic loci (Supplementary Table, sheets 19 and 20), e.g., at epilepsy-relevant genes like Spp1 (78) in neurons and Atf3 (79) in glia. Differential gene expression and differential DNA methylation coincide at epilepsy-related loci in both the CLH and ILH, yet the overlap of differential methylation between the CLH and ILH is marginal. There are no genomic loci in both the CLH and ILH at which differential DNA methylation and differential gene expression coincide in both hippocampi. While several previous studies revealed various associations between DNA methylation and gene expression in epilepsy (28, 29, 75), more recent studies have claimed a more restricted importance of DNA methylation for gene expression in epilepsy (80). The general role of DNA methylation for the regulation of gene expression appears to be highly tissue- and context-specific (81) and may not be the primary factor determining gene expression in early epileptogenesis. Thus, how changes in DNA methylation are related to differential gene expression in early epileptogenesis remains unclear.

Limitations

Considered a solid marker of mature neurons (82, 83), NeuN (Rbfox3) may not stain all CNS neurons (84). As such, the NeuN- fraction (referred to as glia) may, apart from astrocytes, oligodendrocytes, and microglia, contain a minor fraction of non-glial cells (e.g., endothelial cells, pericytes, and neurons) (84–86).

At steady state, RNA sequencing (RNAseq) is a solid approach for the estimation of protein abundance, and as such, biological function, yet in transition states, distortions in this correlation may occur (17, 18). Hence, we may under- or overestimate biological effects based on our interpretation of the differential gene expression results 24 h after injection. Also, posttranscriptional (87) and posttranslational mechanisms (88) may account, among other things, for a non-linear correlation between mRNA and protein abundance. These shortcomings may also contribute to an explanation as to why the CLH, which features many of the same differentially regulated gene transcripts as the ILH, does not feature morphological alterations.

A previous study on gene expression revealed a mainly stage-specific (acute, latent, or chronic) gene expression profile in epileptogenesis (89). As such, the comparison of our gene set, representing relatively acute changes of kainic acid-induced status epilepticus, to previous data from a chronic time point of epileptogenesis (43) should be interpreted with caution.

Regarding the only marginal overlap of differential DNA methylation between the CLH and ILH and the non-existent overlap of genomic loci with the association between differential gene expression and differential DNA methylation, one possible cause is that the method for detecting differential DNA methylation, RRBS, does not include all CpGs (37). RRBS covers most CpGs in promoters and CpG islands (but not all) and has a low coverage at, for example, CpG shores and enhancers (37). We might ergo have missed specific genomic loci at which differential DNA methylation and differential gene expression coincide.

CONCLUSION

In this study we found substantial changes in gene expression and DNA methylation 24 h after status epilepticus in the mouse hippocampus contralateral to the site of kainate injection. This begs the question why the CLH, in contrast to the ILH, does not develop hippocampal sclerosis? In the CLH we found an overweight of upregulated genes with potential anti-epileptogenic properties. Further, we detected a significantly lower number of differentially regulated genes in glia. We therefore hypothesize that both an overweight of upregulated genes and pathways with potential downstream anti-epileptogenic effects and a lower number of genes and pathways with pro-epileptogenic qualities in glia contribute to prevent epileptogenesis in the CLH. Gene expression changes in terms of nuclear mRNA may, however, only be one among many factors when it comes to finally determining cellular responses upon external stimuli. Also the role of DNA methylation for gene expression remains still uncertain in this model as we only found...
a marginal overlap of differentially methylated sites between the CLH and ILH. In order to further disentangle the cell- and stage-specific orchestration of epileptogenesis, it is essential to perform longitudinal animal studies including the investigation of acute and chronic time points of epileptogenesis. Finally, studies exploring neuronal and glial gene expression in human tissue are required in order to evaluate the clinical relevance of these findings.

DATA AVAILABILITY STATEMENT

Raw data is available under GEO accession code GSE153976.

ETHICS STATEMENT

The animal study was reviewed and approved by Norwegian Food Safety Authority, the Center for Comparative Medicine, Oslo University Hospital and the University of Oslo.

AUTHOR CONTRIBUTIONS

TB: conceptualization, data curation, formal analysis, investigation, methodology, project administration, validation, visualization, writing–original draft, and writing–review & editing. KH: conceptualization, funding acquisition, investigation, methodology, project administration, resources, supervision, validation, writing–original draft, and writing–review & editing. KS: conceptualization, funding acquisition, methodology, project administration, resources, supervision, and writing–review & editing. ET: conceptualization, methodology, project administration, supervision, and writing–review & editing. CN: investigation and writing–review & editing. HH: conceptualization, investigation, methodology, project administration, writing–original draft, and writing–review & editing. MV: conceptualization, data curation, formal analysis, methodology, project administration, software, supervision, validation, visualization, writing–original draft, and writing–review & editing. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Pitkanen A, Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav. (2009) 14(Suppl. 1):16–25. doi: 10.1016/j.ybbeh.2008.09.023
2. Pitkanen A, Engel J Jr. Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics. (2014) 11:231–41. doi: 10.1007/s13311-014-0257-2
3. Wieser HG. ILAE commission report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia. (2004) 45:695–714. doi: 10.1111/j.0013-9580.2004.06004.x
4. Patel DC, Tewari BP, Chaunsali L, Sontheimer H. Neuron–glia interactions in the pathophysiology of epilepsy. Nat Rev Neurosci. (2019) 20:282–97. doi: 10.1038/s41583-019-0126-4
5. Mathern GW, Babb TL, Vickrey BG, Melendez M, Pretorius JK. The clinical-pathogenic mechanisms of hippocampal neuron loss and surgical outcomes in temporal lobe epilepsy. Brain. (1995) 118:105–18. doi: 10.1093/brain/118.1.105
6. Houser CR. Granule cell dispersion in the dentate gyrus of humans with temporal lobe epilepsy. Brain Res. (1990) 535:195–204. doi: 10.1016/0006-8993(90)91601-C
7. Houser C, Miyashiro J, Swartz B, Walsh G, Rich J, Delgado-Escueta A. Altered patterns of dynorphin immunoreactivity suggest mossy fiber reorganization in human hippocampal epilepsy. J Neurosci. (1990) 10:267–82. doi: 10.1523/JNEUROSCI.10-01-00267.1990
8. De Lanerolle NC, Kim HJ, Robbins RJ, Spencer DD. Hippocampal interneuron loss and plasticity in human temporal lobe epilepsy. Brain Res. (1989) 495:387–95. doi: 10.1016/0006-8993(89)90234-5

FUNDING

This project has participated in the European Commission, ERA-NET NEURON, Brain Inflammation, Glia and Epilepsy (KH), and has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 722053 (to KH). The project was also funded from South-Eastern Norway Regional Health Authority, No. 2014018 (KS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

ACKNOWLEDGMENTS

The Sequencing service was provided by the Norwegian Sequencing Centre (www.sequencing.uio.no), a national technology platform hosted by Oslo University Hospital and the University of Oslo supported by the Research Council of Norway and the Southeastern Regional Health Authority. We would like to thank Professor Frank Kirchhoff for his excellent leadership of the EU Glia PhD Consortium. We would like to thank Professor Christian Steinhäuser and Ph.D. Peter Bedner from the Institute of Cellular Neurosciences, University of Bonn Medical Center for their help in establishing and traineeship on the animal model, consistent advice, and friendship. We would like to thank Ph.D. Hans Christian D. Aass (The Flow Cytometry Core Facility, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway) for sorting nuclei and providing Supplementary Figure 4 [taken from (22)]. We would also like to thank Ph.D. Rune Enger (Glia Lab and Letten Centre, Department of Molecular Medicine, Division of Physiology, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway) for providing graphical visualizations of the hippocampi used in Figures 1–3. Parts of Figure 3 were modified from images provided by https://smart.servier.com/ under a Creative Commons Attribution 3.0 Unported License.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.573575/full#supplementary-material
9. Tauck DL, Nadler JV. Evidence of functional mossy fiber sprouting in hippocampal formation of kainic acid-treated rats. J Neurosci. (1985) 5:1016–22. doi: 10.1523/JNEUROSCI.05-04-01016.1985

10. Blumcke I, Thom M, Aronica E, Armstrong DD, Bartolomei F, Bernasconi A, et al. International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a task force report from the ilae commission on diagnostic methods. Epilepsia. (2013) 54:1315–29. doi: 10.1111/epi.12220

11. Bedner P, Dupper A, Huttmann K, Muller J, Herde MK, Dublin P, et al. Astrocyte uncoupling as a cause of human temporal lobe epilepsy. Brain. (2015) 138:1208–22. doi: 10.1093/brain/awv067

12. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia. (2005) 46:1724–43. doi: 10.1111/j.1528-1167.2005.00298.x

13. Rigau V, Morin M, Roussel MC, De Bock F, Lebrun A, Coubes P, et al. Angiogenesis Is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain. (2007) 130:1942–56. doi: 10.1093/brain/awm118

14. Seifert G, Steinhäuser C. Neuron–Astrocyte signaling and epilepsy. Exp Neurol. (2013) 244:4–10. doi: 10.1016/j.expneurol.2011.08.024

15. Pitkanen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol. (2011) 10:173–86. doi: 10.1016/S1474-4422(10)70310-0

16. Loscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discover. (2013) 12:757–6. doi: 10.1038/nrd4126

17. Liu Y, Beyer A, Aebbersold R. On the dependency of cellular protein levels on mrna abundance. Cell. (2016) 165:535–50. doi: 10.1016/j.cell.2016.03.014

18. Silva GM, Vogel C. Quantifying gene expression: the importance of being subtle. Mol Syst Biol. (2016) 12:885. doi: 10.15252/msb.20167325

19. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, et al. A Transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci. (2008) 28:264–78. doi: 10.1523/JNEUROSCI.4178-07.2008

20. Doyle JP, Dougherty JD, Heiman M, Schmidt EF, Stevens TR, Ma G, et al. Ryley Parrish R, Albertson AJ, Buckingham SC, Hablitz J, Mascia KL, Davis et al. Status epilepticus triggers early and late alterations in brain-derived neurotrophic factor and NMDA glutamate receptor Grin2b DNA methylation levels in the hippocampus. Neuroscience. (2013) 248:602–19. doi: 10.1016/j.neuroscience.2013.06.029

21. Guo J, Ma DK, Mo H, Ball MP, Jiang MH, Bonaguidi MA, et al. Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci. (2011). 14:1345–51. doi: 10.1038/nn.2900

22. Anderson OS, Sartor MA. Annotatr: genomic regions in context. Science. (2013) 341:1237905. doi: 10.1126/science.1237905

23. Rakhade SN, Jensen FE. Epileptogenesis in the immature brain: emerging mechanisms. Nat Rev Neurol. (2009) 5:380–91. doi: 10.1038/nrneurol.2009.80

24. Nol F, Cattalini A, Vila Verde D, Alessi C, Colciaghi F, Figini M, et al. Epileptiform activity contralateral to unilateral hippocampal sclerosis does not cause the expression of brain damage markers. Epilepsia. (2019) 60:1184–99. doi: 10.1111/epi.15611

25. Jiang Y, Matveossian A, Huang H-S, Kraubhaar J, Akbarian S. Isolation of neuronal chromatin from brain tissue. BMC Neuroscience. (2008) 9:42. doi: 10.1186/1471-2202-9-42

26. Boyle P, Clement K, Gu H, Smith ZD, Ziller M, Fostel JL, et al. Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling. Genome Biol. (2012) 13:R92. doi: 10.1186/gb-2012-13-10-r92

27. Liao Y, Smyth GK, Shi W, The R package Rsquared is easier, faster, cheaper and better for alignment and quantification OF RNA sequencing reads. Nucleic Acids Res. (2019) 47:e47. doi: 10.1093/nar/gkj214

28. Wickham H. Ggplot2: Elegant Graphics For Data Analysis. New York, NY: Springer (2016).

29. Cavalcante RG, Sartor MA. Annotatr: genomic regions in context. Bioinformatics. (2017) 33:2381–3. doi: 10.1093/bioinformatics/btx183

30. Robinson MD, McCarthy DJ, Smyth GK. Edger: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. (2010) 26:139–40. doi: 10.1093/bioinformatics/btp616

31. Chen Y, Pal B, Visvader JE, Smyth GK. Differential methylation analysis of reduced representation bisulfite sequencing experiments using edger. F1000Res. (2017) 6:2055. doi: 10.12688/f1000research.13196.1

32. Winden KD, Karsten SL, Bragin A, Kudo LC, Gehman L, Ruidera J, et al. A systems level, functional genomics analysis of chronic epilepsy. PLoS ONE. (2011) 6:e20763. doi: 10.1371/journal.pone.0020763

33. Lukasiuk K, Dabrowski M, Adach A, Pitkanen A. Epileptogenesis-related genes revisited. Prog Brain Res. (2006) 158:223–41. doi: 10.1016/S0079-6123(06)58011-2

34. Griffin NG, Wang Y, Hulette CM, Halvorsen M, Cronin KD, Walley NM, et al. Differential gene expression in dentate granule cells in mesial temporal lobe epilepsy with and without hippocampal sclerosis. Epilepsia. (2016) 57:376–85. doi: 10.1111/epi.13305

35. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, et al. Genomic analysis of reactive astroglia. J Neurosci. (2012) 32:6391–410. doi: 10.1523/JNEUROSCI.6221-11.2012

36. Pitkanen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol. (2002) 1:173–81. doi: 10.1016/S1474-4422(02)00073-X

37. Sutula TP, Hagen J, Pitkanen A. Do epileptic seizures damage the brain? Curr Opin Neurol. (2003) 16:189–95. doi: 10.1097/00010522-200304000-00012

38. Rossini L, Garbelli R, Gnatkovsky V, Didato G, Villani F, Sprefico R, et al. Seizure activity per se does not induce tissue damage markers in human neocortical focal epilepsy. Ann Neurol. (2017) 82:331–41. doi: 10.1002/ana.25005

39. Lerner JT, Sankar R, Mazarati AM. Galanin and epilepsy. Cell Mol Life Sci. (2006) 65:1864–71. doi: 10.1007/s00018-008-8161-8

40. Wickham J, Ledri M, Bengzon J, Jespersen B, Pinborg LH, Englund E, et al. Inhibition of epileptiform activity by neuropeptide y in brain tissue from drug-resistant temporal lobe epilepsy patients. Sci Rep. (2019) 9:19393. doi: 10.1038/s41598-019-56602-1

41. Baker BJ, Akhtar LN, Benveniste EN. SOC31 and SOC3S in the control of CNS immunity. Trends Immunol. (2009) 30:392–400. doi: 10.1016/j.it.2009.07.001
53. Jimenez-Mateos EM, Bray I, Sanz-Rodriguez A, Engel T, McKiernan RC, Mouri G, et al. Mirna expression profile after status epilepticus and hippocampal neuroprotection by targeting Mir-132. *Am J Pathol*. (2011) 179:2519–32. doi: 10.1016/j.ajpath.2011.07.036

54. Ganganossa G, Di Benedetto M, O’Sullivan GJ, Dunleavy M, Alacer C, Bonito-Olive A, et al. Convulsant doses of A dopamine D1 receptor agonist result in Erk-Dependent increases in Zif268 and Arc/Arg3.1 expression in mouse dentate gyrus. *Plos ONE*. (2011) 6:e19415. doi: 10.1371/journal.pone.0019415

55. Rojas A, Jiang J, Ganesh T, Yang MS, Gao H, Lee WL, Yeo TS, et al. Metabotropic glutamate receptor 2/3 in the hippocampus of patients with mesial temporal lobe epilepsy, and of rats and mice after pilocarpine-induced status epilepticus. *Epilepsy Res*. (2004) 59:167–80. doi: 10.1016/j.eplepsyres.2004.04.002

56. Xia MQ, Bacskai BJ, Knowles RB, Qin SX, Hyman BT. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer’s disease. *J Neuroimmunol*. (2000) 108:227–35. doi: 10.1016/S0165-5728(00)00285-X

57. Tang FR, Chia SC, Chen PM, Gao H, Lee WL, Yeo TS, et al. The chemokine CXCL10 modulates excitatory activity in neurons of the central auditory system. *Mol Neurobiol*. (2014) 51:312–8. doi: 10.1007/s12035-015-9122-5

58. Iughetti L, Lucaccioni L, Fugetto F, Predieri B, Berardi A, Ferrari F. Brain-derived neurotrophic factor and epilepsy: a systematic review. *Neuropathol Appl Neurobiol*. (2011) 37:312–8. doi: 10.1111/j.1365-2990.2011.01153.x

59. Iwamoto K, Bundo M, Ueda J, Oldham MC, Ukai W, Hashimoto E, et al. Neurons show distinctive DNA methylation profile and higher interindividual variations compared with non-neurons. *Genome Res*. (2011) 21:688–96. doi: 10.1101/gr.112755.110

60. Nelson TE, Gruol DL. The chemokine CXCL10 modulates excitatory activity in neurons of the central auditory system. *Mol Neurobiol*. (2014) 51:312–8. doi: 10.1007/s12035-015-9122-5

61. Miller-Delaney SF, Das S, Sano T, Jimenez-Mateos EM, Bryan K, Buckley PG, et al. Differential DNA methylation patterns define status epilepticus and epileptic tolerance. *J Neurosci*. (2012) 32:1577–88. doi: 10.1523/NEUROSCI.1580.11.2012

62. Ma DK, Jiang M-H, Guo JU, Kitabatake Y, Chang M-L, Pow-Appongkul N, et al. Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. *Science*. (2009) 323:1074–7. doi: 10.1126/science.1166859

63. Oh JW, El-Osta A, Kaspi A, Ziemann M, Khurana I, Kn H, et al. Transcription factors Tp73, Cebp, Pax6, And Spi1 rather than DNA methylation regulate chronic transcriptomics changes after experimental traumatic brain injury. *Acta Neuropathol Commun*. (2016) 21:675–8. doi: 10.1007/s12035-015-9122-5

64. Berger et al. *Epi*genomic Analysis of Early Epileptogenesis. *Frontiers in Neurology* [Online] 20 November 2020; Volume 11 [Article 573575]